Organogenesis to Submit Biologics License Application for ReNu Therapy Targeting Knee Osteoarthritis Pain

Organogenesis, a regenerative medicine company, has announced the successful completion of a meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational product ReNu®. The company confirmed plans to submit a Biologics License Application (BLA) for ReNu®, which is being developed as a treatment for knee osteoarthritis pain.

According to the announcement, the FDA meeting focused on finalizing details related to the BLA submission process. Organogenesis reported that it received feedback from the agency and outlined next steps for advancing ReNu® toward regulatory approval. The company stated that it intends to proceed with filing the BLA in alignment with FDA guidance. ReNu® is an allogeneic therapy designed to address chronic knee osteoarthritis pain, a condition affecting millions of individuals in the United States. Further updates on the timeline for submission or additional clinical data were not disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 6, 2026

Author

GOAI